Labeled Somatostatin Analogues in Theranostics of Neuroendocrine Tumors

Чернов,; Чернов, В. И.; Bragina, Zinaida; Bragina, Olga; Зельчан,; Zelchan, Roman; Medvedeva,; Medvedeva, A. A.; Синилкин,; Синилкин, И. Г.; Ларькина,; Larkina, Maria; Стасюк,; Stasyuk, E. S.; Нестеров,; Нестеров, Е. А.; Скуридин,; Скуридин, В. С.

doi:10.12737/article_5927f627a5c123.67647794

Cited by 7 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Первые клинические исследования свидетельствуют о том, что 99m Тс1тиоD глюкоза займет достойное место в диагностике и стадировании лимфом (рис. 9) [19,20] Тсоктреотид специфично и пропорционально экспрессии рецепторов соматостатина [29,30].…”

Section: Doi: 1037174/258775932020342638unclassified

Innovative Radiopharmaceuticals for Cancer Diagnosis and Treatment

Чернов

Медведева

Zelchan

et al. 2020

jour

View full text Add to dashboard Cite

The presented material summarizes the experience of Cancer Research Institute and Tomsk Polytechnical University team in the development of original radiopharmaceuticals (RP) for nuclear medicine. The first such unique for world nuclear medicine RP was a Thallium199. The Thallium199 is successfully used for breast cancer diagnosis and its lymphogenous metastasis, as well as to visualize cancer of the larynx and laryngopharynx, their relapses and for differential diagnosis of inflammatory and tumor processes of the musculoskeletal system. The great practical importance for nuclear medicine has the organization of a wastefree production of sorption and extraction generators of Technetium-99m at the IRTT TPU nuclear research reactor, as well as the creation of a fully automated 99mTc module operating on a waste free technology. The development of the 99mTcAlotech for targeting imaging of sentinel lymph nodes (SLN) has also great importance for clinical oncology. The main advantage of 99mTcGlucoscin is that metabolic tumor imaging with the innovative RP use can be performed using a conventional gamma camera, which significantly reduces the cost of the diagnostic procedure. The present and promising developments of the research teams of the Tomsk Scientific Research Center and the Tomsk Polytechnic University are closely related to theranostics — the use of RPs obtained on the basis of same target compound labeled with different isotopes intended for the diagnosis or therapy of oncological diseases.

show abstract

Section: Doi: 1037174/258775932020342638unclassified

Innovative Radiopharmaceuticals for Cancer Diagnosis and Treatment

Чернов

Медведева

Zelchan

et al. 2020

jour

View full text Add to dashboard Cite

show abstract

“…In this regard, it is still necessary to search for new informative diagnostic methods for detection of malignant tumors with overexpression of Her-2/neu. In recent years, the radioisotope techniques are developing for detection of specific tumor targets [7]. One of the most studied components for the formation of specific relations with the isotopes are "targeting" non-immunoglobulin molecules DARPins (designed ankyrin repeat proteins), which belong to a novel class of binding molecules with the potential to overcome the limitations of monoclonal antibodies, hence allowing novel therapeutic approaches.…”

mentioning

confidence: 99%

In vitro evaluation of a specific radiochemical compound based on 99mTc-labeled DARPinG3 for radionuclide imaging of tumors overexpressing Her-2/neu

Bragina

Larkina

Stasyuk

et al. 2017

AIP Conference Proceedings

Self Cite

View full text Add to dashboard Cite

It is still necessary to search for new informative diagnostic methods to detect malignant tumors with overexpression of Her-2/neu, which are characterized by the aggressive course of the disease, rapid rate of tumor growth and low rates of relapse-free and overall survival. In recent years, the radioisotope techniques for detection of specific tumor targets have been developing actively. Purpose: to develop a chemically stable radiochemical compound for the targeted imaging of cells overexpressing Her-2/neu. Material and methods: The study was performed using 2 cell lines. The human breast adenocarcinoma HER2-overexpressing cell line BT-474 was chosen to detect specific binding. As a control, HER2-negative human breast adenocarcinoma MCF-7 was used. The human breast adenocarcinoma BT-474 and MCF-7 cell lines were seeded in chamber-slides at the density of 35,000 cells/ml in trypsin-EDTA (PanEco) medium and grown overnight at 37°C. After that both cell lines were washed with Phosphate buffered saline (PBS) and distributed into test tubes to 1 ml (5 millions cells in each). After adding 100 μl (70 MBq) studied complex of 99mTc-DPAH-DARPinG3 was incubated for 40 min at +4°C. Washing was performed three times with buffer PBS and 5% Bovine Serum Albumin (BSA). The characteristics of the binding specificity of the test set with the HER-2/neu receptor were determined by direct radiometric and planar scintigraphy. Nonparametric Mann-Whitney test was used to assess the differences in the quantitative characteristics between groups. Results: The output of the labeled complex was more than 91%, with a radiochemical purity of more than 94%. When carrying out a visual scintigraphic assessment much greater intensity accumulation of radiotracer was observed in the studied cell culture surface receptor overexpressing Her-2/neu. The results of direct radiometric also showed higher accumulation of the radiopharmaceutical in the adenocarcinoma cell line BT-474 human breast cancer overexpressing Her-2/neu compared to the control group. Conclusion: The preclinical studies demonstrated a high in vitro stability of the study compound, as well as its accumulation in the cell group overexpressing Her-2/neu.

show abstract